The approval of the therascreen® PIK3CA PCR assay as a companion diagnostic to detect PIK3CA gene mutations in tissue or plasma has brought the use of liquid biopsy as a diagnostic tool closer to patients with breast cancer. The gene discussed is PIK3CA; the disease is breast carcinoma.